18:46 , Jul 21, 2017 |  BC Week In Review  |  Company News

OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs

Abzena plc (LSE:ABZA) granted OBI Pharma Inc. (TPEx:4174) exclusive, worldwide rights to ThioBridge antibody drug conjugate (ADC) linker- technology which OBI will use to develop its preclinical cancer candidate OBI-999 and other undisclosed ADCs to...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

OBI-822/821: Phase II/III data

Top-line data from a double-blind, international Phase II/III trial in 349 treatment-experienced patients with histologically or cytologically confirmed metastatic breast cancer showed that OBI-822/821 plus low-dose cyclophosphamide missed the primary endpoint of improving PFS vs....
02:39 , Feb 23, 2016 |  BC Extra  |  Clinical News

OBI breast cancer therapy misses Phase II/III endpoint

OBI Pharma Inc. (TPEx:4174) said OBI-822/821 missed the primary endpoint of progression free survival (PFS) in a top-line analysis of its Phase II/III study to treat metastatic breast cancer. The company said the data showed...
16:23 , Dec 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4

Cancer INDICATION: Cancer Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines. Chemical synthesis identified a series of modified globo-H antigens that could be coupled to...
07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Optimer Pharmaceuticals Inc. Inc. cancer news

Optimer plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to treat metastatic breast...
00:38 , Oct 9, 2012 |  BC Extra  |  Company News

Optimer selling stake in Taiwan subsidiary for $60M

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; prostate cancer Globohexaosylceramide (globo-H); ganglioside GM2 (GM2); Thomsen-Friedenreich antigen (TF); Tn antigen (Tn); sialosyl-Tn antigen (sTn) In vitro studies suggest that a pentavalent...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Clinical News

GPI-0100: Phase I data

In a dose-escalation, U.S. Phase I trial in 42 evaluable patients with relapsed prostate cancer, GPI-0100 used in combination with a bivalent vaccine was well tolerated and led to a dose-dependent enhanced immune response. Bivalent...
07:00 , Oct 7, 2002 |  BC Week In Review  |  Company News

Optimer, Memorial Sloan-Kettering Cancer Center deal

Optimer received an exclusive global license for Globo H vaccine from the center to treat breast and prostate cancer. Optimer will oversee marketing of the vaccine, which is in clinical development. Optimer also has rights...